UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
| ||||||||||||||||||||||||||||||
|
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | SEC 1473 (7-02) | ||
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. |
1. Title of Derivative Security (Instr. 4) |
2. Date Exercisable and Expiration Date (Month/Day/Year) |
3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) |
4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5) |
6. Nature of Indirect Beneficial Ownership (Instr. 5) |
||
Date Exercisable | Expiration Date | Title | Amount or Number of Shares | ||||
Stock Option (Right to Buy) | 10/29/2006(3) | 09/28/2016 | Common Stock | 22,006 | $ 2.57 | D | |
Stock Option (Right to Buy) | 10/29/2006(3) | 09/28/2016 | Common Stock | 27,994 | $ 2.57 | D |
Reporting Owner Name / Address | Relationships | |||
Director | 10% Owner | Officer | Other | |
Kaster Kevin R C/O THRESHOLD PHARMACEUTICALS, INC. 1300 SEAPORT BOULEVARD, 5TH FLOOR REDWOOD CITY, CA 94063 |
Sr. VP Corporate Development |
/s/ Harold E. Selick, Attorney-in-fact | 03/22/2007 | |
**Signature of Reporting Person | Date |
* | If the form is filed by more than one reporting person, see Instruction 5(b)(v). |
** | Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). |
(1) | Subject to a right of repurchase by Threshold Pharmaceuticals, Inc. which right of repurchase will lapse as to 1/48th of the shares on equal monthly installments commencing on 03/10/2004. |
(2) | Subject to a right of repurchase by Threshold Pharmaceuticals, Inc. which right of repurchase will lapse as to 25% of the shares on May 12, 2005 and 1/48 of the shares in equal monthly installments beginning June 12, 2005. |
(3) | This option began to vest and became exercisable commencing on September 29, 2006 in equal monthly installments, with the last installment vesting on January 1, 2010. |